Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 19Colorectal Neoplasms 16Esophageal Neoplasms 13Barrett Esophagus 8Colonic Neoplasms 7Rectal Neoplasms 6Gastrointestinal Neoplasms 6Colonic Polyps 6Neoplasms 3Duodenal Neoplasms 3Adenoma, Villous 3Adenocarcinoma Of Esophagus 3Rectal Neuroendocrine Tumors 2Precancerous Conditions 2Lung Neoplasms 2Hemorrhage 2Gastric GIST 2Esophageal Squamous Cell Carcinoma 2Carcinoma, Non-Small-Cell Lung 2Adenoma 2Tobacco Use Disorder 1Submucosal Tumor of Stomach 1Small Size Gastrointestinal Stromal Tumors 1Small Cell Lung Carcinoma 1Predictive Cancer Model 1Polyps 1Polyposis, Gastric 1Pituitary Neoplasms 1Personal Satisfaction 1Pathological Conditions, Anatomical 1

Interventions

trifluridine tipiracil drug combination 1berzosertib 1Trifluridine 1Taxes 1Ramucirumab 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Irinotecan 1Endoscopy 1Endoscopic Mucosal Resection 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Clinical Stage III Gastric Cancer AJCC v8 × Endoscopic Mucosal Resection × Clear all
NCT03641313 2026-04-13

Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
17 enrolled 14 charts
Gastrointestinal

Clinical Stage III Gastric Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡